SELLAS Life Sciences met second quarter 2026 EPS estimates while advancing pivotal Phase 3 REGAL trial

SELLAS Life Sciences reported a net loss for the second quarter of 2026 that met analyst expectations, despite a significant increase in operating expenses associated with late-stage clinical preparations. The company substantially improved its liquidity position and remains focused on reaching the final data analysis trigger for its lead leukemia program.

Key Highlights

• Research and development expenses rose to $6.3 million from $3.9 million in the prior year, primarily due to BLA manufacturing preparations for galinpepimut-S (GPS).
• The company ended the quarter with $138.3 million in cash and cash equivalents, a significant increase from $71.8 million at the end of fiscal 2025.
• The pivotal Phase 3 REGAL trial of GPS in AML is currently approaching the pre-specified 80th event trigger required to commence the final efficacy analysis.